Immunitybio Stock
StockStockPrice
Frequently asked questions
What is Immunitybio's market capitalization?
What is the Earnings Per Share (EPS) for Immunitybio?
What are the analyst ratings and target price for Immunitybio's stock?
What is Immunitybio's revenue over the trailing twelve months?
What is the EBITDA for Immunitybio?
What is the free cash flow of Immunitybio?
What is the 5-year beta of Immunitybio's stock?
How many employees does Immunitybio have, and what sector and industry does it belong to?
What is the free float of Immunitybio's shares?
Financials
Market Cap
$3.37B5Y beta
0.74EPS (TTM)
-$0.867Free Float
159.61MRevenue (TTM)
$7.33MEBITDA (TTM)
-$340.77MFree Cashflow (TTM)
-$434.10MPricing
Analyst Ratings
The price target is $7.50 and the stock is covered by 2 analysts.
Buy
1
Hold
1
Sell
0
Information
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its proprietary platforms that amplify both the innate and adaptive branches of the immune system, its advances therapies and vaccines to defeat urologic and other cancers, as well as infectious diseases. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising, B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA and recombinant protein vaccines, and cell therapies. Its lead biologic commercial product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein.
672
Biotechnology & Drugs
Health Care
Identifier
ISIN
Primary Ticker